Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Overview of attention for article published in Lancet Oncology, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 3 news outlets
twitter: 24 X users
patent: 2 patents

f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 373 Mendeley

So far, Altmetric has seen 1 Guideline that references this research output.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

Clinical guideline published by Society for Immunotherapy of Cancer (SITC) on 09 Jun 2023

The Society for Immunotherapy of Cancer (SITC) is a leading organization dedicated to advancing cancer immunotherapy. It focuses on improving patient outcomes through education, research, and the development of clinical practice guidelines. SITC promotes collaboration and innovation in the field, aiming to make immunotherapy a standard treatment for cancer.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.